Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience

被引：8

作者：

Sood A. ^{[1
]}

Midha V. ^{[1
]}

Sharma S. ^{[1
]}

Sood N. ^{[1
]}

Bansal M. ^{[1
]}

Thara A. ^{[1
]}

Khanna P. ^{[1
]}

机构：

[1] Dayanand Medical College, Ludhiana, 141 001, DMC Road, Tagore Nagar

来源：

Indian Journal of Gastroenterology | 2014年 / 33卷 / 1期

关键词：

Biologicals; Inflammatory bowel disease; Rescue therapy;

D O I：

10.1007/s12664-013-0372-8

中图分类号：

学科分类号：

摘要：

Introduction: The role of infliximab in the treatment of acute severe ulcerative colitis is established. However, all the data available in the literature are from western countries. This is the first report on the use of infliximab in patients with severe steroid-refractory ulcerative colitis from India. Methods: Retrospective analysis of 28 patients who had received infliximab therapy for induction of remission, with three doses of 5 mg/kg at 0, 2, and 6 weeks, was performed. Results: Twenty-four (85.6 %) patients had shown a clinical response by week 8 and, hence, avoided urgent colectomy. In 2 years of follow up, 9/16 (56 %) patients had not required colectomy. Conclusion: Infliximab averted colectomy in a proportion of patients with severe steroid-refractory ulcerative colitis. © 2013 Indian Society of Gastroenterology.

引用

页码：31 / 34

页数：3

共 11 条

[1]

Porro G.B., Cassinotti A., Ferrara E., Maconi G., Ardizzone S., Review article: the management of steroid dependency in ulcerative colitis, Aliment Pharmacol Ther., 26, pp. 779-794, (2007)

[2]

Kozuch P.L., Hanauer S.B., Treatment of inflammatory bowel disease: a review of medical therapy, World J Gasteroenterol., 14, pp. 354-377, (2008)

[3]

Knight D.M., Trin H., Le J., Et al., Construction and initial characterization of a mouse-human chimeric anti-TNF antibody, Mol Immunol., 30, pp. 1443-1453, (1993)

[4]

Rutgeerts P., Sandborn W.J., Feagan B.G., Et al., Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, pp. 2462-2476, (2005)

[5]

Reinisch W., Sandborn W.J., Rutgeerts P., Et al., Long-term infliximab maintenance therapy for ulcerative colitis: the ACT1 and ACT2 extension studies, Inflamm Bowel Dis, 18, pp. 201-211, (2012)

[6]

Lichtiger S., Present D., Kornbluth A., Et al., Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Eng J Med., 330, pp. 1841-1845, (1994)

[7]

Willert R.P., Lawrance I.C., Use of infliximab in the prevention and delay of colectomy in severe steroid dependent and refractory ulcerative colitis, World J Gastroenterol., 14, pp. 2544-2549, (2008)

[8]

Aratari A., Papi C., Clemente V., Et al., Colectomy rate in acute severe ulcerative colitis in the infliximab era, Dig Liver Dis., 40, pp. 821-826, (2008)

[9]

Jarnerot G., Hertervig E., Friis-Liby I., Et al., Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study, Gastroenterology., 128, pp. 1805-1811, (2005)

[10]

Probert C.S., Hearing S.D., Schreiber S., Et al., Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial, Gut., 52, pp. 998-1002, (2003)

← 1 2 →